Genetic Factors Affecting the Severity of Beta Thalassemia

Status Completed

Clinical Trial Summary

Patients with genetic diseases can have widely differing severities. We are looking for genetic factors which influence the severity of beta thalassemia.

Clinical Trial Description

The understanding of the phenotypic variability of genetically homogeneous disorders represents a major challenge. In beta thalassemia, the beta globin gene is affected by a variety of mutations. The group of patients to be analyzed here is homozygous for a splice site mutation that is common in the Middle East. In contrast to this genetic homogeneity, the spectrum of the clinical phenotype ranges from mild anemia to most severe, transfusion dependent anemia. We will use a genetic linkage approach to identify modifying factors and by analyzing the efficiency of an mRNA surveillance mechanism that is referred to as nonsense-mediated decay and represents a candidate genetic modifier of beta thalassemia and other genetic disorders. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00159042
Study type	Observational
Source	Hadassah Medical Organization
Contact
Status	Completed
Phase	N/A
Start date	July 2004
Completion date	July 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01049854` - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant	Phase 2
Active, not recruiting	`NCT00408447` - Stem Cell Transplant in Sickle Cell Disease and Thalassemia	Phase 2
Completed	`NCT02597595` - Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major	N/A
Recruiting	`NCT06073860` - A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
Recruiting	`NCT05357482` - Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia	Phase 1/Phase 2
Completed	`NCT00790127` - Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia	Phase 1/Phase 2
Completed	`NCT00005934` - 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia	Phase 2
Completed	`NCT01931644` - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Recruiting	`NCT04929574` - Evaluation of Heart Status in Patients of Beta Thalassemia Using Echocardiogram
Recruiting	`NCT04918056` - Genetic Variants Affecting the Clinical Severity of Beta Thalassemia
Completed	`NCT00001958` - Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)	Phase 2
Recruiting	`NCT04917978` - Association of Hb F Level With Clinical Severity of Beta Thalassemia